The beneficial properties of mint for irritable bowel syndrome and beyond

Initial note: this article was originally published in the past and has been updated according to scientific and divulgative criteria. The content is for informational purposes only and does not replace medical advice. For clinical concerns, consult your doctor.

IN BRIEF

• Peppermint (especially Mentha × piperita) contains menthol, which exerts antispasmodic effects through multiple biological mechanisms.
• Numerous reviews and clinical studies suggest a short-term benefit of peppermint oil capsules in irritable bowel syndrome (IBS), but the quality of evidence varies.
• The plausible effect is mediated by relaxation of intestinal smooth muscle and modulation of sensory receptors (e.g., TRPM8), not by a single causal mechanism.
• Enteric formulations and targeted delivery systems can influence efficacy and tolerability; precautions exist for certain hepatobiliary conditions and pregnancy.

Abstract: what does science say?

Peppermint, particularly the essential oil of Mentha × piperita and its main component menthol, has been studied for the symptomatic treatment of functional gastrointestinal disorders such as irritable bowel syndrome (IBS). Aggregated clinical evidence (reviews and meta-analyses) shows an improvement in global symptoms and abdominal pain compared to placebo in several short-term studies; however, results from more recent trials with stricter endpoints are sometimes conflicting. Plausible biological mechanisms include antispasmodic action through modulation of calcium channels and activation of sensory receptors like TRPM8, in addition to antimicrobial and anti-inflammatory properties. The effect depends on the dose, pharmaceutical form (e.g., enteric capsules vs. unprotected oil), and duration of treatment. Methodological limitations, heterogeneity of formulations, and possible adverse events necessitate cautious interpretation; the choice of a product must consider the quality of the dosage and the individual patient's conditions.

History and traditional uses

Peppermint is one of the most widespread aromatic herbs, used for centuries in Europe and other medical traditions. In classical sources and folk medicine, it is associated with digestive, carminative, and refreshing properties. Traditional uses include herbal teas for digestive disorders, topical applications for respiratory ailments, and the use of the oil to relieve cramps and abdominal pain. These historical observations have stimulated modern research on the main active ingredient, menthol, which is now being studied for its effects on intestinal smooth muscle, the visceral sensory system, and bile composition. The long history of use supports the plausibility of clinical interest, but does not replace the need for controlled data to define efficacy, dosages, and safety in contemporary contexts.

Plausible biological mechanisms

Experimental literature indicates multiple modes of action for peppermint oil and menthol. Preclinical studies have documented an antispasmodic effect through the inhibition of calcium channel-dependent processes in intestinal muscle cells, explaining the smooth muscle relaxation observed in vitro and in animal preparations [1]. In parallel, menthol activates TRPM8 receptors, responsible for the "cool" sensation, and has been implicated in the modulation of nociceptive afference with analgesic effects in experimental models [2]. Molecular insights into TRPM8 binding dynamics help understand pharmacological activity and potential differences between derivatives and isomers [3]. Finally, the pharmacokinetic profile indicates that menthol is absorbed and metabolized with biliary excretion, with metabolites that may undergo enterohepatic circulation; this is relevant for the site and duration of action and for possible hepatobiliary effects [4]. Overall, biological plausibility is supported by multiple experimental data, but the clinical effect depends on the pharmaceutical form, dose, and the region of the intestine where the active ingredient is released.

Clinical evidence on irritable bowel syndrome

Available clinical evidence includes randomized studies, systematic reviews, and meta-analyses. Aggregate reviews have shown an improvement in global symptoms and abdominal pain with peppermint oil compared to placebo in numerous short-term studies [5][6]. However, more recent trials with modern diagnostic criteria and endpoints (Rome IV, regulatory endpoints) have yielded less clear results, highlighting the importance of study quality and the type of formulation used [7]. Studies on enteric or ileocolonic release formulations have explored the hypothesis that targeting the site of action improves efficacy and tolerability; physiological and pharmacokinetic results support differences in systemic and local concentrations depending on release [8]. Overall, the synthesis of evidence suggests a modest but consistent benefit on some IBS symptoms in the short term; the magnitude of the effect and its long-term persistence remain subjects of study and depend on dosage, formulation, and the studied population.

Quality of studies and endpoints

Many clinical studies on peppermint oil are of moderate size, with generally short durations (4–8 weeks) and variance in definitions of improvement. Previous meta-analyses combine trials with different formulations and diagnostic criteria, a condition that can increase heterogeneity and limit causal interpretation. More recent trials adopting endpoints based on regulatory guidelines (reported pain reduction) offer stricter data and in some cases less convergent results; this underlines the importance of individually evaluating methodological quality, blinding, and compliance when reading the literature.

Safety and tolerability

In clinical studies, the most reported adverse events include epigastric burning, reflux, and mild gastrointestinal reactions. Enteric formulations reduce esophageal irritation but do not completely eliminate side effects. Pharmacological and pharmacokinetic literature highlights hepatic metabolism and biliary excretion of menthol, therefore caution is advised in the presence of liver diseases or obstruction of the bile ducts [4]. Occasional signals of liver toxicity associated with products containing essential oils with high concentrations of potentially hepatotoxic components have been published; therefore, evaluating product quality and impurity content is relevant from a safety perspective [9].

What it means in practice

For the general public, evidence indicates that the use of enteric peppermint oil in capsules can offer short-term relief for some individuals with IBS, especially for abdominal pain and cramps. Efficacy is not universal and varies based on the person, dose, and formulation. The plausible action is antispasmodic and modulation of visceral sensitivity, not a cure for the condition. If considering use: choose products with dosages documented in clinical studies, prefer enteric formulations to reduce reflux or burning, consult a doctor in case of liver disease, gallstones, or unexplained symptoms. Avoid using undiluted oil orally; during pregnancy and in pediatric age, prescription should be evaluated by professionals. Finally, peppermint oil can be part of a multimodal approach (diet, behavioral therapy, medications when indicated) but does not replace specific therapies decided by the doctor.

Key points to remember

• Menthol is the main bioactive component and has antispasmodic and sensory modulating effects.
• Meta-analyses and RCTs show improvements in IBS symptoms in the short term, but study quality is variable.
• The pharmaceutical form (enteric, ileocolonic) influences efficacy and tolerability.
• Precautions in the presence of liver disease, gallstones, or pregnancy.
• There is no evidence that the use of peppermint negates the need for medical evaluations for new or severe symptoms.

Limitations of evidence

It is important to distinguish observational studies, which can suggest associations, from causal evidence obtained from randomized controlled trials. Many works on the topic are short-term, with limited samples and use heterogeneous endpoints; this reduces the strength of conclusions. Combined reviews may suffer from formulation heterogeneity and publication bias. Furthermore, the effect observed in an experimental setting on musculature or receptors does not always translate into general clinical benefit: context, dosage, method of administration, and patient characteristics influence the results. For these reasons, practical recommendations must be cautious and personalized. Further well-designed, longer-duration trials with regulatory clinical endpoints are needed to clarify efficacy, responsive patient subgroups, and long-term safety profile.

Editorial conclusion

Peppermint and its derivative menthol represent an emblematic case of a traditional remedy that has found partial confirmation in modern research: plausible biological mechanisms and favorable short-term clinical results for some IBS symptoms. However, study heterogeneity, formulation variability, and tolerability signals require caution. For patients considering use, informed product selection with clinical evidence and preventive medical evaluation are essential steps. Future research should focus on rigorous trials with standardized clinical endpoints, comparisons between formulations, and long-term safety evaluations to consolidate practical indications.

Editorial note

Article updated according to scientific and divulgative criteria. The information reported here is for informational purposes only and does not replace professional medical advice. Always consult your doctor for personalized therapeutic decisions.

SCIENTIFIC RESEARCH

1. Hawthorn M, Ferrante J, Luchowski E, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988 Apr;2(2):101-118. https://doi.org/10.1111/j.1365-2036.1988.tb00677.x
2. Liu B, Fan L, Balakrishna S, et al. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain. 2013 Oct;154(10):2169-2177. https://doi.org/10.1016/j.pain.2013.06.043
3. Yuan C, et al. (studies on TRPM8 gating) Implications of Human TRPM8 Channel Gating from Menthol Binding Studies. Biochemistry. 2015. https://doi.org/10.1021/acs.biochem.5b00931
4. Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine. 2005 Aug;12(8):612-616. https://doi.org/10.1016/j.phymed.2004.10.007
5. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505-512. https://doi.org/10.1097/MCG.0b013e3182a88357
6. Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19:21. https://doi.org/10.1186/s12906-018-2409-0
7. Keszthelyi D, et al. Efficacy and safety of peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123-136. https://doi.org/10.1053/j.gastro.2019.08.026
8. Weerts Z, et al. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Adv Ther. 2018. https://doi.org/10.1007/s12325-018-0802-1
9. Iraji A, et al. Peppermint and menthol: a review on their biochemistry, pharmacological activities, clinical applications, and safety considerations. Crit Rev Food Sci Nutr. 2023. https://doi.org/10.1080/10408398.2023.2296991